BioXcel Therapeutics Inc
NASDAQ:BTAI
Intrinsic Value
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. [ Read More ]
The intrinsic value of one BTAI stock under the Base Case scenario is 6.66 USD. Compared to the current market price of 2.82 USD, BioXcel Therapeutics Inc is Undervalued by 58%.
Valuation Backtest
BioXcel Therapeutics Inc
Run backtest to discover the historical profit from buying and selling BTAI stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of BioXcel Therapeutics Inc's business.
What risks and challenges
does BioXcel Therapeutics Inc face in the near future?
Summarize the latest earnings report
of BioXcel Therapeutics Inc.
Provide P/E
for BioXcel Therapeutics Inc and its competitors.
Balance Sheet Decomposition
BioXcel Therapeutics Inc
Current Assets | 98.7m |
Cash & Short-Term Investments | 90m |
Receivables | 700k |
Other Current Assets | 8m |
Non-Current Assets | 1.7m |
PP&E | 1.6m |
Other Non-Current Assets | 100k |
Current Liabilities | 39.4m |
Accounts Payable | 10.7m |
Accrued Liabilities | 27.4m |
Other Current Liabilities | 1.3m |
Non-Current Liabilities | 101.7m |
Long-Term Debt | 99.1m |
Other Non-Current Liabilities | 2.6m |
Earnings Waterfall
BioXcel Therapeutics Inc
Revenue
|
1.4m
USD
|
Cost of Revenue
|
-1.3m
USD
|
Gross Profit
|
120k
USD
|
Operating Expenses
|
-167.7m
USD
|
Operating Income
|
-167.6m
USD
|
Other Expenses
|
-11.4m
USD
|
Net Income
|
-179.1m
USD
|
Free Cash Flow Analysis
BioXcel Therapeutics Inc
What is Free Cash Flow?
BTAI Profitability Score
Profitability Due Diligence
BioXcel Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
BioXcel Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
BTAI Solvency Score
Solvency Due Diligence
BioXcel Therapeutics Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
BioXcel Therapeutics Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BTAI Price Targets Summary
BioXcel Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for BTAI is 13.52 USD with a low forecast of 4.04 USD and a high forecast of 26.25 USD.
Ownership
BTAI Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
BTAI Price
BioXcel Therapeutics Inc
Average Annual Return | 64.85% |
Standard Deviation of Annual Returns | 151.17% |
Max Drawdown | -97% |
Market Capitalization | 82.6m USD |
Shares Outstanding | 30 381 900 |
Percentage of Shares Shorted | 45.98% |
BTAI News
Last Important Events
BioXcel Therapeutics Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
BioXcel Therapeutics Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The company is headquartered in New Haven, Connecticut and currently employs 89 full-time employees. The company went IPO on 2018-03-08. The company is focused on utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. Its two advanced clinical development programs are BXCL501, which is an investigational, orally dissolving, sublingual thin film formulation of the adrenergic receptor agonist dexmedetomidine (Dex) for the treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, which is an investigational orally administered systemic innate immune activator for the treatment of castration resistant prostate cancer and advanced solid tumors that are refractory or treatment nave to checkpoint inhibitors. The company is conducting a Phase 1b/2 trial of BXCL701 in combination with KEYTRUDA (pembrolizumab) for metastatic castration-resistant prostate cancer (mCRPC), in patients with adenocarcinoma and in patients with the aggressive variant small-cell neuroendocrine carcinoma.
Contact
IPO
Employees
Officers
The intrinsic value of one BTAI stock under the Base Case scenario is 6.66 USD.
Compared to the current market price of 2.82 USD, BioXcel Therapeutics Inc is Undervalued by 58%.